Management of hot flashes in women with breast cancer

L. Kligman RNEC and J. Younus MD

ABSTRACT

Hormone-suppression therapies are used for the treatment of breast cancer in the adjuvant and metastatic settings alike. However, side effects—including hot flashes—are frequently reported by patients as a cause of therapy discontinuation. This paper presents an overview of hormonal therapies and the evidence-based management options for hot flashes, summarized in a treatment algorithm.

KEY WORDS

Breast cancer, hot flashes, tamoxifen, aromatase inhibitors

1. INTRODUCTION

In 2008, an estimated 22,400 women in Canada were diagnosed with breast cancer, making that disease the most common cancer in women. Treatment includes any combination of surgery, chemotherapy, and radiation therapy. For women with cancers positive for the estrogen or the progesterone receptor (or both), hormone suppression is an additional option. Because hormone-suppressive treatment can span five or more years, care is often shared with or transferred to family physicians and community nurse practitioners.

In premenopausal women, the ovaries produce about 95% of circulating estrogen; in postmenopausal women, conversion or aromatization of androstenedione to estrone in peripheral tissues is the major source of estrogen. Approximately half of all women diagnosed with breast cancer will have a hormone-sensitive tumour. Blocking uptake of estrogen at the receptor level or suppressing estrogen and progesterone production therefore becomes a goal of treatment.

2. OVERVIEW OF HORMONE THERAPIES

Tamoxifen, a selective estrogen receptor modulator, has both antagonist and agonist properties, blocking the effect of estrogen in breast tissue, but showing estrogen-like activity in other tissues. The indication for the use of tamoxifen has been expanded to include adjuvant treatment of both pre- and postmenopausal women. Male breast cancers commonly express the estrogen and progesterone receptors and can also be treated with tamoxifen.

Unlike tamoxifen, fulvestrant is a pure estrogen receptor antagonist with no agonist effects. It works by both downregulating and degrading the estrogen receptor. It is given once monthly as an injection. Currently, it is indicated for use only in hormone-sensitive metastatic breast cancer.

The identification of aromatase as an essential enzyme in the peripheral conversion of testosterone to estradiol led to the development of further options for hormone suppression. Aromatase inhibitors are used only in postmenopausal women to prevent stimulation of ovarian estrogen production through negative feedback to the hypothalamus and pituitary (analogous to the functional properties of fertility drugs). Current agents in this class include anastrozole, letrozole, and exemestane.

Hormone suppression is now standard treatment for pre- and postmenopausal women with advanced and early forms of hormone-sensitive breast cancer. Clinical trials such as ATAC (Anastrozole Alone or in Combination), BIG (Breast International Group) 1-98, and IES (Intergroup Exemestane Study) have shown a small but significant additional benefit of aromatase inhibitors alone or in sequential combination with tamoxifen in improving disease-free survival. Other trials are ongoing.

Almost all national and international guidelines recommend inclusion of an aromatase inhibitor in the treatment plan for hormone-positive tumours in postmenopausal women. However, for both pre- and postmenopausal women, frequently reported side effects include hot flashes, arthralgia, weight gain, hair thinning, dyspareunia, vaginal dryness, and loss of libido. In some cases, these side effects may be severe enough for patients to stop, independently reduce the dosage of, or otherwise alter potentially life-saving treatment regimens. Information from clinical trials has revealed that approximately 25% of women do not adhere to therapy and that this percentage increases to 50% for women not in clinical trials. Because aromatase
inhibition or tamoxifen treatment is intended to last for at least 5 years, successful management of these side effects becomes paramount in increasing patient compliance and optimal outcome. The present review focuses on management options for one of these side effects: hot flashes.

3. CLINICAL DESCRIPTION AND PATHOPHYSIOLOGY

Hot flashes are commonly defined as recurring transient episodes of flushing and sweating, with a sensation of heat, often accompanied by palpitations or anxiety, and sometimes followed by chills. A population-based survey comparing women having breast cancer with women in the general population determined that breast cancer survivors were 5.3 times more likely than women in the general population to experience menopausal symptoms. Several theories have been posited for the pathophysiology of hot flashes. A decline in estrogen has been suggested to cause a change in the thermoregulatory set point in the anterior portion of the hypothalamus. The thermoregulatory nucleus initiates perspiration and vasodilatation to keep core body temperature within a well-regulated range called the thermoregulatory zone. Researchers have demonstrated a narrowing of the zone between sweating and shivering in symptomatic women, so that small elevations within the zone cause a change in hormones or neurotransmitters, producing a hot flash. Yet correlations of the frequency and severity of hot flashes with plasma or serum estrogen levels are poor, suggesting that other mechanisms may be involved.

Serotonin has repeatedly been proved to be an important regulator of body temperature, and its action appears to be time- and dose-dependent. For example, drug-induced excess of 5-hydroxytryptamine has been noted to induce malignant hyperthermia. The thermoregulatory set point has been suggested to possibly depend on a balance of two or more serotonin receptors. Changes in the balance, possibly related to the direct or indirect action of estrogen, could theoretically induce a vasomotor response.

Functional estrogen receptors have been found in human vascular smooth muscle, suggesting that estrogen may also have a direct and important role in vascular function. Recent research has also shown a correlation between plasma estradiol levels and baroreflex sensitivity.

The regulation of core body temperature is likely to be ultimately found to involve complex interactions of norepinephrine, estrogen, testosterone, serotonin, and endorphins in neuroendocrine pathways.

Hot flashes emerged as a significant adverse effect in all of the aromatase inhibitor trials (Table 1). The ATAC trial (Trial to Assess Response to Gefitinib in EGFR-mutated Tumors) compared anastrozole with tamoxifen as first-line treatment in postmenopausal women with advanced breast cancer. Hot flashes were reported in 19.6% of women receiving anastrozole as compared with 18.8% of those receiving tamoxifen. In the ATAC adjuvant trial comparing anastrozole with tamoxifen, 35.7% of women on anastrozole reported hot flashes as compared with 40.9% of women on tamoxifen (p < 0.0001). Letrozole and tamoxifen were compared in the BIG 1-98 trial, and hot flashes were reported in 33.5% of women receiving letrozole and in 38% of those receiving tamoxifen (p < 0.001). The IES trial compared the steroidal aromatase inhibitor exemestane with tamoxifen. In that trial, hot flashes were reported in 42% of patients treated with exemestane and in 39.6% of those receiving tamoxifen (p = 0.082).

Little information is available about the duration or severity of hot flashes, but the IES trial did publish quality-of-life data indicating that this symptom decreased over time. Some predictors of increased hot flash severity or frequency are known. These include previous history of estrogen replacement therapy, history of moderate to severe hot flashes during menopause in postmenopausal women, premature treatment-induced menopause at a young age, obesity, and smoking (direct relationship with number of cigarettes smoked).

4. REVIEW OF MANAGEMENT OPTIONS

In 2004, a nurse-run hot flash clinic was started at the London Regional Cancer Program. The purpose of

| Reference | Trial | Hot flashes (%) with | p Value |
|-----------|-------|---------------------|--------|
|           | short name | Anastrozole | Tamoxifen | Letrozole | Exemestane |
| Bonneterre et al., 2001 | ATAC | 35.7 | 40.9 | | 0.0001 |
| Bonneterre et al., 2003 | TARGET | 19.6 | 18.8 | | Not reported |
| Coombes et al., 2004 | IES | 39.6 | 42 | | 0.082 |
| Coates et al., 2007 | BIG 1-98 | 38 | 33.5 | | 0.001 |

a Thurlimann B, for the BIG 1-98 Collaborative. Letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer: first results of IBCSG 18-98/BIG 1-98. Presented at the Ninth International Conference on Primary Therapy of Early Breast Cancer; January 26, 2005; St. Gallen, Switzerland.
In the clinic was to evaluate evidence-based treatment of hot flashes and to advance symptom management research. A stepwise approach based on efficacy data, tolerability, and local clinical experience is suggested for management (Figure 1, Table i).

Inclusion of a survey of side effects as part of the follow-up assessment of women receiving hormone-suppressive therapy is imperative. The initial assessment of hot flashes should include onset, baseline number and severity, effect on measures of quality of life such as sleep and work, and any known patterns or triggers. Often, patterns emerge and links can be made with triggers such as caffeine, smoking, and alcohol. Reduction of these risk factors is recommended. It is sometimes helpful to review lifestyle interventions such as dressing in layers, use of cotton clothing and bedding, strategic placement of electric fans, and the carrying of cold drinks. Reusable cooling bandanas containing polymer crystals may be helpful. They can be soaked in cold water for 10–30 minutes and tied around the neck for a long-lasting cooling effect. Results from these changes are usually seen within the first 1 to 2 weeks of use.

In small, controlled investigations, progressive muscle relaxation and paced respiration techniques have been shown to significantly reduce objectively measured hot flash occurrence. In a larger randomized controlled trial of 150 women with primary breast cancer who were trained in deep-breathing techniques, muscle relaxation, and guided imagery, hot flash severity declined significantly over 1 month.

**Figure 1** Treatment algorithm for hot flashes, based on the experience of the London Regional Cancer Program.
Distress also significantly declined, but no difference in quality of life between the control group and the treatment group was observed. Hypnosis may also provide a non-pharmacologic option for women who prefer to avoid medications. In 2005, a case report of the successful use of hypnosis to treat hot flashes and rheumatic symptoms was published. In a subsequent randomized trial of hypnosis as an intervention for hot flashes, a 68% reduction in hot flash scores was demonstrated in 60 breast cancer survivors as compared with a control group. Additional benefit was seen in parameters such as sleep, anxiety, and depression.

Estrogen replacement, the most effective treatment for menopausal symptoms, is generally not recommended after a diagnosis of breast cancer. The HABITS (Hormonal Replacement Therapy After Breast Cancer Diagnosis—Is It Safe?) trial randomized 434 women with a previous diagnosis of breast cancer to receive either hormone replacement therapy (HRT) or best supportive care without hormones. The endpoint of the trial was any new breast cancer event. After 2.1 years, 26 women in the HRT group (versus 8 in the no-HRT group) had experienced a new breast cancer event (relative hazard: 3.5; 95% confidence interval: 1.5 to 8.1). The trial was terminated December 17, 2003, because of unacceptable risk.

Breast cancer patients suffering hot flashes are often bombarded with information from well-intentioned friends and family members regarding alternative and complementary remedies, and those remedies are seen by many women with breast cancer as a more attractive option than traditional medicines. Unfortunately, few placebo-controlled trials of non-pharmacologic agents have been conducted, and those that have been conducted show marginal benefits at best.

### Table II: Review of treatment options for hot flashes in breast cancer patients

| Reference and management option | Effect | Reduction (% in Composite hot flash score) | Placebo p Value |
|--------------------------------|--------|------------------------------------------|----------------|
| Freedman and Woodward, 1992    | Reduced distress | 39 | 0.02 |
| Freedman et al., 1995          | Reduced distress | 44 | 0.001 |
| Loprinzi et al., 2000          | Improved quality of life | 34.2 | 21.1 | 0.001 |
| Stearns et al., 2003           | Improved quality of life and libido | 46 | 19 | 0.001 |
| Pandya et al., 2005            | Decreased pain, worse appetite | 28 | 18 | 0.0002 |
| Gabapentin 300 mg daily        | Decreased pain, worse appetite | 49 | 21 | 0.0001 |
| Gabapentin 900 mg daily        | Decreased pain, worse appetite | 33 | 21 | 0.0001 |
| Elkins et al., 2008            | Improved mood and sleep, decreased interference with daily life | 68 | Not used | 0.001 |
| Fenton et al., 2008            | Reduced distress | 50 | 22 | (clinically nonsignificant) |
| Sexton et al., 2007            | Improved | 65 | Not used | 0.0001 |
studies are problematic because of small sample size and conflicting results. Most of these remedies are phytoestrogens that are structurally similar to estradiol. Phytoestrogens can be found in foods such as beans, seeds, and grains. They include products such as black cohosh, red clover, evening primrose oil, and soy, and depending on the dose, they work either to block estrogen receptors or to mimic estrogen. Their effect on an estrogen-sensitive breast cancer cell is unknown, and at the present time there is not enough evidence to advise women that these products are safe.

Clinical trials of pharmacologic agents have noted the significant placebo effect that any intervention can have on hot flashes. It has been reported in numerous clinical trials that the placebo effect can decrease hot flashes by approximately 50%.

Data collected from patient diaries and outcomes are typically reported in two ways: using a composite hot flash score consisting of the frequency, duration, and mean severity of each episode; or using separate effects, such as change in frequency and severity.

A few pharmacologic agents have shown varying degrees of efficacy for treating hot flashes. For some of these, side effects limit their usefulness; others show statistical benefit, but not clinically significant reductions in symptom frequency or intensity. The more successful agents include selective serotonin reuptake inhibitor (SSRI) antidepressants, megestrol acetate, and gabapentin. Antihypertensives such as clonidine have shown modest benefit.

Clonidine, a centrally active alpha agonist that reduces vascular reactivity and norepinephrine release, is used principally for the management of hypertension. It is available in pills and transdermal patches. Transdermal clonidine was found to reduce the frequency of hot flashes by 20% and the severity by a modest 10%.

In another trial, Pandya et al. randomized 194 postmenopausal women on adjuvant tamoxifen therapy to receive either a placebo or oral clonidine 0.1 mg daily for 8 weeks. Decrease in frequency of hot flashes was greater for the clonidine group (38%) than for the placebo group (20%), with benefit also noted in measures of intensity and duration.

Other studies have shown increasing benefit with higher doses.

The SSRIs antidepressants have also shown efficacy, with the greatest response noted in the breast cancer population. Loprinzi et al. conducted a randomized placebo-controlled trial of venlafaxine in 191 breast cancer survivors complaining of hot flashes. Within that group, 69% were receiving tamoxifen. The trial randomized women to one of four treatment groups: three groups received venlafaxine in doses of 37.5 mg, 75 mg, and 150 mg; the fourth group received placebo. After 4 weeks, benefit was seen in the 75 mg dose group, with 63% of participants reporting more than 50% reduction in hot flashes. No additional benefit was seen by increasing the dose to 150 mg.

A later study by Evans et al. confirmed these results in a non-breast cancer population. Other antidepressants in this class have also shown efficacy, although concern has arisen that some are producing the response by blocking the efficacy of an active tamoxifen metabolite, endoxifen, which utilizes the same CYP2D6 pathway in the liver. The data suggest that citalopram and venlafaxine are least likely to effect CYP2D6 activity and that paroxetine and fluoxetine are more potent inhibitors and should be avoided.

The anticonvulsant gabapentin has been studied for hot flash management. A 2005 study by Pandya et al. randomized 420 women with breast cancer and experiencing at least 2 hot flashes in 24 hours to one of three groups: gabapentin 300 mg daily, gabapentin 900 mg daily, or placebo. After 8 weeks, the 300 mg dose group showed a modest 20% reduction in hot flashes, but the 900 mg dose group showed a reduction of approximately 46%. Interestingly, three quarters of the patients in the 900 mg dose group requested and were granted permission to increase their doses beyond the 900 mg, and they achieved a 67% decrease in hot flash severity.

Megestrol is an oral progestogen that has antitumour activity in postmenopausal patients after failure of other endocrine therapies. A crossover study of megestrol versus placebo demonstrated that hot flashes were reduced by 85% with megestrol 20 mg twice daily. However, in vitro studies have shown that progesterational agents may increase or accelerate breast cancer development or progression, making megestrol a poor choice for management of hot flashes in women. In contrast, it is a very effective treatment for men with prostate cancer who are on hormone manipulation and suffering hot flashes.

In 2007, a case series using oxybutynin for management of hot flashes was reported by members of the breast disease site team at the London Regional Cancer Program. This antimuscarinic agent was observed to reduce hot flashes, providing a complete response in approximately 70% of patients who had been refractory to other treatments. The recommended dose is 2.5 mg either once or twice daily; side effects typical of anticholinergic medications are generally mild and well tolerated.

5. SUMMARY

Hot flashes are a significant problem for quality of life in breast cancer patients. They likely contribute to poor compliance with hormone-suppressive therapies. Family physicians, oncologists, and nurses can play an important role both in assessing hot flashes and in reviewing and tailoring treatment options to individual patient needs.

6. REFERENCES

1. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247–58.
2. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486–92.
3. Coombes RC, Hall E, Gibson LJ, et al. on behalf of the Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.

4. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602–6.

5. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772–80.

6. Harris PF, Remington PL, Trentham–Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002;23:501–9.

7. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000;36:155–64.

8. Hoda D, Perez DG, Loprinzi CL. Hot flashes in breast cancer survivors. Breast J 2002;8:5–10.

9. Freedman RR, Krell W. Reduced thermoregulatory null zone in menopausal women. Menopause 1993;5:405–9.

10. Sheard MH, Aghajanian GK. Neural release of brain serotonin and body temperature. Nature 1967;216:495–6.

11. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999;13:100–9.

12. Stearns V, Ullmer L, López JF, Smith Y, Isaacs C, Hayes D. Hot flashes. Lancet 2002;360:1851–61.

13. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptors. Circulation 1994;89:1943–50.

14. Tanaka M, Sato M, Umehara S, Nishikawa T. Influence of menstrual cycle on baroreflex control of heart rate: comparison with male volunteers. Am J Physiol Regul Integr Comp Physiol 2003;285:R1091–7.

15. Bonnettre J, Thürilmann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748–57.

16. Howell A, Cuzick J, Baum M, et al. on behalf of the ACOSG Trialists’ Group. Results of the ACOSG (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–2.

17. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006;24:910–17.

18. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulf KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003;101:264–72.

19. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flashes: evaluation by ambulatory monitoring. Am J Obstet Gynecol 1992;167:436–9.

20. Freedman R, Woodward S, Brown B, Jawaid J, Pandey G. Biochemical and thermoregulatory effects of behavioral treatment for menopausal hot flashes. Menopause 1995;2:211–18.

21. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–63.

22. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758–64.

23. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818–24.

24. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol 2008;26:5022–6.

25. Fenlon DR, Corner JL, Haviland JS. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. J Pain Symptom Manage 2008;35:397–405.

26. Sexton T, Younus J, Perera F, Kligman L, Lock M. Oxybutynin for refractory hot flashes in cancer patients. Menopause 2007;14:505–9.

27. Younus J, Welch S, Granville H. A case report of using hypnosis to treat hot flashes and rheumatic symptoms. Case Rep Clin Pract Rev 2005;6:103–6.

28. Holmberg L, Anderson H on behalf of the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453–5.

29. von Schoultz E, Rutqvist LE on behalf of the Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005;97:533–5.

30. Kronenberg F, Fugh–Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805–13.

31. Goldberg RM, Loprinzi CL, O’Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155–8.

32. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788–93.

33. Laufer LR, Ehrlich Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982;60:583–6.

34. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161–6.

35. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer. Am J Psychiatry 2008;165:1251–5.

36. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347–52.

Correspondence to: Lyn Kligman, Supportive Care, London Regional Cancer Program, 790 Commissioners–Road East, London, Ontario N6A 4L6. E-mail: lyn.kligman@lhsc.on.ca